BEIJING, Sept. 29, 2014
/PRNewswire/ -- Following US and European approvals of
Elekta's Versa HD™ linear accelerator, the China Food and Drug
Administration (CFDA) has cleared the radiation therapy system for
sale and marketing in the country.
According to the International Agency for Research on Cancer,
well over three million people are diagnosed with cancer every year
in China1, the most
common types including lung, gastric, colorectal, liver and
esophageal cancers2. Versa HD is designed to improve
patient care and treat a wide range of tumors throughout the
body.
Versa HD is equipped with the Agility™ multileaf collimator for
high-speed, high-precision beam shaping to support extremely
accurate tumor targeting and improved healthy tissue preservation.
Together with High Dose Rate mode, Versa HD is able to improve
clinical workflow by providing rapid delivery of more sophisticated
therapies within standard radiotherapy treatment times.
Elekta's Anming Gong, Managing
Director for China, says: "As
cancer rates continue to rise in China, the need for advanced and effective
treatment becomes even greater. Versa HD will help support the
government's health care reform, which includes upgrading community
and rural health care facilities by 2020."
Versa HD has been overwhelmingly popular since its launch in
2013, with shipments made to 30 countries. Elekta has been present
in China since 1982 and eight of
10 top cancer centers have Elekta linear accelerators. The
introduction of Versa HD will strengthen Elekta's leading position
in the Chinese market.
1Ferlay J, Soerjomataram I, Ervik M, Dikshit R,
Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence
and Mortality Worldwide: IARC CancerBase No. 11 [Internet].
Lyon, France: International Agency
for Research on Cancer; 2013.
2Report of incidence and mortality in China cancer registries, 2009 (doi:
10.3978/j.issn.1000-9604.2012.12.04)
For further information, please contact:
Gert van Santen, Group Vice President Corporate
Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director, Investor
Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make
public in accordance with the Securities Market Act and/or the
Financial Instruments Trading Act. The information was published at
07:30 CET on September 29, 2014.
About Elekta
Elekta is a human care company pioneering
significant innovations and clinical solutions for treating cancer
and brain disorders. The company develops sophisticated,
state-of-the-art tools and treatment planning systems for radiation
therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence
to both health care providers and patients, Elekta aims to improve,
prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in
over 6,000 hospitals worldwide. Elekta employs around 3,800
employees globally. The corporate headquarters is located in
Stockholm, Sweden, and the company
is listed on the Nordic Exchange under the ticker STO:EKTAB.
Website: www.elekta.com.
SOURCE Elekta
